Sol-Gel Technologies Ltd. – NASDAQ:SLGL
Founder-led company
Sol-Gel Technologies Ltd. stock price today
$17.98
+16.86
+1505.36%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Sol-Gel Technologies Ltd. stock price monthly change
+16.67%
month
Sol-Gel Technologies Ltd. stock price quarterly change
+16.67%
quarter
Sol-Gel Technologies Ltd. stock price yearly change
-8.20%
year
Sol-Gel Technologies Ltd. key metrics
Market Cap | 11.48M |
Enterprise value | 84.31M |
P/E | -6.8 |
EV/Sales | 21.71 |
EV/EBITDA | -6.04 |
Price/Sales | 24.72 |
Price/Book | 2.27 |
PEG ratio | 0.01 |
EPS | -0.83 |
Revenue | 1.72M |
EBITDA | -24.95M |
Income | -22.86M |
Revenue Q/Q | -38.52% |
Revenue Y/Y | -62.90% |
Profit margin | -384.42% |
Oper. margin | -418.42% |
Gross margin | 0% |
EBIT margin | -418.42% |
EBITDA margin | -1450.76% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSol-Gel Technologies Ltd. stock price history
Sol-Gel Technologies Ltd. stock forecast
Sol-Gel Technologies Ltd. financial statements
| Jun 2023 | 594K | -5.97M | -1005.05% |
|---|---|---|---|
| Sep 2023 | 213K | -5.71M | -2681.22% |
| Dec 2023 | 447K | -4.83M | -1081.88% |
| Mar 2024 | 466K | -6.34M | -1361.37% |
| Dec 2023 | 447K | -4.83M | -1081.88% |
|---|---|---|---|
| Mar 2024 | 466K | -6.34M | -1361.37% |
| Sep 2025 | 3.9M | -2.22M | -57.14% |
| Dec 2025 | 2.2M | -2.50M | -113.96% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 55103000 | 6.80M | 12.35% |
|---|---|---|---|
| Sep 2023 | 49862000 | 6.73M | 13.51% |
| Dec 2023 | 45287000 | 6.64M | 14.67% |
| Mar 2024 | 39911000 | 7.26M | 18.19% |
| Jun 2023 | 0 | 0 | 0 |
|---|---|---|---|
| Sep 2023 | 0 | 0 | 0 |
| Dec 2023 | 0 | 0 | 0 |
| Mar 2024 | 0 | 0 | 0 |
Sol-Gel Technologies Ltd. alternative data
| Aug 2023 | 55 |
|---|---|
| Sep 2023 | 55 |
| Oct 2023 | 55 |
| Nov 2023 | 55 |
| Dec 2023 | 55 |
| Jan 2024 | 55 |
| Feb 2024 | 55 |
| Mar 2024 | 36 |
| Apr 2024 | 36 |
| May 2024 | 36 |
| Jun 2024 | 36 |
| Jul 2024 | 36 |
Sol-Gel Technologies Ltd. other data
20.89%
-3.74%
of SLGL is owned by hedge funds
4.83M
-865.51K
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 26 Mar 2020 Issue date: 30 Jun 2022 |
Application Filling date: 19 Mar 2020 Issue date: 9 Jun 2022 |
Application Filling date: 24 Jan 2022 Issue date: 12 May 2022 |
Application Filling date: 3 Dec 2021 Issue date: 5 May 2022 |
Application Filling date: 28 Oct 2019 Issue date: 14 Apr 2022 |
Application Filling date: 16 Nov 2021 Issue date: 10 Mar 2022 |
Application Filling date: 9 Nov 2021 Issue date: 3 Mar 2022 |
Application Filling date: 25 Feb 2020 Issue date: 24 Feb 2022 |
Application Filling date: 26 Jul 2021 Issue date: 27 Jan 2022 |
Application Filling date: 27 Jan 2020 Issue date: 13 Jan 2022 |
| Insider | Compensation |
|---|---|
Dr. Alon Seri-Levy (1961) Co-Founder, Chief Executive Officer & Director | $397,000 |
Mr. Gilad Mamlok (1968) Chief Financial Officer | $364,000 |
-
What's the price of Sol-Gel Technologies Ltd. stock today?
One share of Sol-Gel Technologies Ltd. stock can currently be purchased for approximately $17.98.
-
When is Sol-Gel Technologies Ltd.'s next earnings date?
Unfortunately, Sol-Gel Technologies Ltd.'s (SLGL) next earnings date is currently unknown.
-
Does Sol-Gel Technologies Ltd. pay dividends?
No, Sol-Gel Technologies Ltd. does not pay dividends.
-
How much money does Sol-Gel Technologies Ltd. make?
Sol-Gel Technologies Ltd. has a market capitalization of 11.48M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 59.98% to 1.55M US dollars.
-
What is Sol-Gel Technologies Ltd.'s stock symbol?
Sol-Gel Technologies Ltd. is traded on the NASDAQ under the ticker symbol "SLGL".
-
What is Sol-Gel Technologies Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sol-Gel Technologies Ltd.?
Shares of Sol-Gel Technologies Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sol-Gel Technologies Ltd.'s key executives?
Sol-Gel Technologies Ltd.'s management team includes the following people:
- Dr. Alon Seri-Levy Co-Founder, Chief Executive Officer & Director(age: 64, pay: $397,000)
- Mr. Gilad Mamlok Chief Financial Officer(age: 57, pay: $364,000)
-
Is Sol-Gel Technologies Ltd. founder-led company?
Yes, Sol-Gel Technologies Ltd. is a company led by its founder Dr. Alon Seri-Levy.
-
How many employees does Sol-Gel Technologies Ltd. have?
As Jul 2024, Sol-Gel Technologies Ltd. employs 36 workers.
-
When Sol-Gel Technologies Ltd. went public?
Sol-Gel Technologies Ltd. is publicly traded company for more then 7 years since IPO on 1 Feb 2018.
-
What is Sol-Gel Technologies Ltd.'s official website?
The official website for Sol-Gel Technologies Ltd. is sol-gel.com.
-
How can i contact Sol-Gel Technologies Ltd.?
Sol-Gel Technologies Ltd. can be reached via phone at +972 8 931 3433.
Sol-Gel Technologies Ltd. company profile:
Sol-Gel Technologies Ltd.
sol-gel.comExchange:
NASDAQ
Full time employees:
36
Industry:
Biotechnology
Sector:
Healthcare
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
7 Golda Meir Street
Ness Ziona, 7403650
Ness Ziona, 7403650
CIK: 0001684693
ISIN: IL0011417206
CUSIP: M8694L103
